Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its financial results for Q1 2023 on April 25, 2023, before market opening. A conference call is scheduled for 9:00 a.m. Eastern Time, allowing participants to register for questions. The financial details and accompanying slide presentation will be available in the Investor Relations section of their website. Harvard Bioscience specializes in technologies and services for life sciences applications across research and pharmaceutical development, catering to a diverse clientele from academic institutions to contract research organizations globally.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO Jim Green will present at the Sidoti Virtual Investor Conference on March 22-23, 2023. He is scheduled to present on March 22 at 10:00 AM ET, and a live webcast will be accessible through their website. The presentation will also be archived for a limited time. Additionally, the company will facilitate one-on-one meetings with investors on both days.
Harvard Bioscience (Nasdaq: HBIO) announced that Jim Green, Chairman and CEO, will present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 9:45 AM ET. A live webcast of the presentation will be available online and archived on the company's Investor Relations webpage for a limited time. Additionally, virtual one-on-one meetings will be hosted on the same day for interested investors. Harvard Bioscience specializes in developing, manufacturing, and selling technologies for life science applications, serving clients worldwide, including top academic institutions and pharmaceutical companies.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported a Q4 2022 revenue of $28.4 million, marking a 14% decline from the previous year, impacted by $1 million in negative currency effects. Operating loss was $(0.5 million), down from a profit of $1.7 million in Q4 2021. Adjusted operating income was $3.4 million, with an adjusted operating margin of 11.9%. The company anticipates revenue growth in 2023 in the low-to-mid single digits, with improvements in gross margin and adjusted EBITDA. Plans to reduce debt to a ratio of 2 times by year-end were also noted.
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its fourth-quarter financial results for the period ending December 31, 2022, before market open on March 9, 2023. The company will also host a conference call at 8:00 a.m. Eastern Time to discuss these results. Participants wishing to ask questions during the call must register in advance to receive dial-in information. The earnings release and accompanying slide presentation will be accessible on the company's Investor Relations website. Harvard Bioscience specializes in developing technologies and products for life sciences, serving a diverse range of clients globally.
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced the resignation of CFO Michael Rossi, effective December 31, 2022. Jennifer Cote, VP of global finance, will serve as interim CFO. Rossi will assist during the transition until May 10, 2023. CEO Jim Green acknowledged Rossi's key contributions to the company's strategic transformation since 2019. The company is actively searching for a permanent replacement. Harvard Bioscience develops and sells technologies for research and drug development across global markets.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2022 revenues of $26.9 million, a 9% decline year-over-year, driven by a 17% drop in pre-clinical product sales. Gross margin fell due to lower revenues and increased labor/material costs. The company anticipates Q4 revenues to reach approximately $30 million, with improved operating margins between 14%-15%. Key product launches include the Ultrospec 7500 and continuous glucose monitoring devices. Cost optimization efforts are expected to yield $4 million in annual gross margin improvements.
Harvard Bioscience (Nasdaq: HBIO) will release its third-quarter financial results for 2022, covering the period ending September 30, after market close on November 8, 2022. A conference call to discuss the results will take place at 4:30 p.m. ET the same day. Interested participants can register online for dial-in information and a unique PIN number. The earnings release and presentation materials will be accessible on the company's Investor Relations website.
Harvard Bioscience (Nasdaq: HBIO) reported Q2 2022 revenues of $29.2 million, flat year-over-year, with growth in cellular/molecular product revenues offset by declines in pre-clinical revenues and adverse currency effects. Adjusted operating income decreased to $3.1 million due to higher R&D and marketing costs. GAAP operating income rose to $4.0 million thanks to a $4.9 million litigation settlement. Looking ahead, the company anticipates 1-5% revenue growth for the year and plans to reduce its workforce by 5% as part of a strategic optimization.
Harvard Bioscience (Nasdaq: HBIO) is set to announce its Q2 financial results for the period ending June 30, 2022, before the market opens on August 4, 2022. A conference call will follow at 8:00 AM ET for discussions on the financial results.
Participants interested in joining the call can register here.